A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine. / The standard treatment for rattlesnake envenomation (RSE) is antivenom.
The clinical course of patients treated with antivenom is well described.
Prior to 2000, only a whole IgG AV (IgGAV) associated with high rates of
hypersensitivity reactions (HSS) was available to treat RSE. Since 2000,
Crotalidae Polyvalent Immune Fab (FabAV), which has a better safety profile
than IgGAV, has been primarily used.
Patients with RSE may not be treated with AV for a variety of reasons
including history or perceived risk of HSS, patient refusal, drug shortage, or
clinical impression that AV is not indicated.
Research Question: What outcomes are associated with moderate to severe
RSEs treated without antivenom?
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/627152 |
| Date | 28 March 2018 |
| Creators | Chang, Phoebe |
| Contributors | The University of Arizona College of Medicine - Phoenix, Curry, Steven MD |
| Publisher | The University of Arizona. |
| Source Sets | University of Arizona |
| Language | en_US |
| Detected Language | English |
| Type | Thesis |
| Rights | Copyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. |
Page generated in 0.0017 seconds